Biogen Idec Inc. (NASDAQ:BIIB), maker of the multiple sclerosis drugs Avonex, Tysabri and Tecfidera, said fourth-quarter profit rose 57 percent on higher sales. Biogen Idec Inc (NASDAQ:BIIB), stock opened at $299.03 in last session, and closed at $305.46, while the day range of BIIB stock is $292.82 – $318.42. The stock showed a negative weekly performance of -1.64%.
CytRx Corporation (NASDAQ:CYTR), stock opened at $7.06, in last session and closed at $7.36, by gaining 2.22%. The 52 week range of CytRx Corporation (NASDAQ:CYTR) is $1.83 – $8.24. Company’s market capitalization is $308.94million.
On January 7, 2014, Acadia Pharmaceuticals, Inc.’s (Acadia) stock ended trading at $23.61, compared to the previous day’s closing price of $24.70, representing a 4.41% decline. The Company’s stock went down by 6.12% over the past three trading days, compared to the Dow Jones Industrial Average, which went up by 0.54% over the same trading period. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), stock decreased -1.86% and finished the last session at $23.22. The EPS of the stock remained -0.42. Company’s market capitalization is $2.11billion.
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP), announced that it will announce the results of its Phase 2a clinical trial for the company’s ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes on Jan. 30. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP), stock opened the session at $25.86, and closed the session at $25.97. The 52 week range of the ORMP stock remained $5.00 – $31.73 and the day range was $24.28 – $26.50.